Biodexa Pharmaceuticals
BDRX
3 hedge funds and large institutions have $31.2K invested in Biodexa Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, reducing their positions, and 2 closing their positions.
8.15% more ownership
Funds ownership: 0% → 8.15% (+8.2%)
25% less funds holding
Funds holding: 4 → 3 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
82% less capital invested
Capital invested by funds: $169K → $31.2K (-$138K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GI
GAMMA Investing
Foster City,
California
|
+$15.8K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$3.96K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFM
Boothbay Fund Management
New York
|
-$120K |
| 2 |
Renaissance Technologies
New York
|
-$31K |
BDRX Hedge Fund Activity: Q1 2024 in Review
3 of the 6,961 institutional investors tracked by Wall St. Rank reported a position in Biodexa Pharmaceuticals (BDRX) for Q1 2024, worth a combined $31.2K — down 82% from $169K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of BDRX and 1 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 1 added.
The largest buyer was GAMMA Investing, adding an estimated $15.8K. The largest seller was Boothbay Fund Management, exiting entirely with an estimated $120K sold.
- 3 institutional investors held Biodexa Pharmaceuticals (BDRX) as of Q1 2024, down from 4 in Q4 2023.
- Funds reported $31.2K of Biodexa Pharmaceuticals stock for Q1 2024, down 82% quarter-over-quarter.
- 1 fund opened new Biodexa Pharmaceuticals positions in Q1 2024 and 2 closed out, a net change of -1 holder.
- The largest Biodexa Pharmaceuticals buyer in Q1 2024 was GAMMA Investing, an estimated $15.8K added.
- The largest Biodexa Pharmaceuticals seller in Q1 2024 was Boothbay Fund Management, an estimated $120K sold.
Based on aggregated 13F filings for Q1 2024.